• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疫苗突破感染中来自 SARS-CoV-2 奥密克戎和德尔塔变异株的中和抗体免疫。

Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.

机构信息

Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.

Gladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.

出版信息

Cell. 2022 Apr 28;185(9):1539-1548.e5. doi: 10.1016/j.cell.2022.03.019. Epub 2022 Mar 18.

DOI:10.1016/j.cell.2022.03.019
PMID:35429436
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8930394/
Abstract

Virus-like particle (VLP) and live virus assays were used to investigate neutralizing immunity against Delta and Omicron SARS-CoV-2 variants in 259 samples from 128 vaccinated individuals. Following Delta breakthrough infection, titers against WT rose 57-fold and 3.1-fold compared with uninfected boosted and unboosted individuals, respectively, versus only a 5.8-fold increase and 3.1-fold decrease for Omicron breakthrough infection. Among immunocompetent, unboosted patients, Delta breakthrough infections induced 10.8-fold higher titers against WT compared with Omicron (p = 0.037). Decreased antibody responses in Omicron breakthrough infections relative to Delta were potentially related to a higher proportion of asymptomatic or mild breakthrough infections (55.0% versus 28.6%, respectively), which exhibited 12.3-fold lower titers against WT compared with moderate to severe infections (p = 0.020). Following either Delta or Omicron breakthrough infection, limited variant-specific cross-neutralizing immunity was observed. These results suggest that Omicron breakthrough infections are less immunogenic than Delta, thus providing reduced protection against reinfection or infection from future variants.

摘要

病毒样颗粒 (VLP) 和活病毒检测被用于研究 128 名接种个体的 259 个样本中的针对 Delta 和奥密克戎 SARS-CoV-2 变体的中和免疫。在突破 Delta 感染后,与未感染加强和未加强个体相比,针对 WT 的滴度分别升高了 57 倍和 3.1 倍,而奥密克戎突破感染仅升高了 5.8 倍和 3.1 倍。在免疫功能正常、未加强的患者中,Delta 突破感染引起的针对 WT 的滴度比奥密克戎高 10.8 倍(p=0.037)。与 Delta 相比,奥密克戎突破感染中的抗体反应下降可能与更高比例的无症状或轻症突破感染有关(分别为 55.0%和 28.6%),与中重度感染相比,针对 WT 的滴度低 12.3 倍(p=0.020)。在 Delta 或奥密克戎突破感染后,观察到有限的变体特异性交叉中和免疫。这些结果表明,奥密克戎突破感染的免疫原性低于 Delta,从而降低了对再次感染或未来变体感染的保护作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8930394/758c9ab78bdd/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8930394/2e67ff0f6f1d/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8930394/52a7b30e409a/figs1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8930394/fbf0e4e6da65/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8930394/7d9adba156d1/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8930394/9fad7a9944fb/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8930394/758c9ab78bdd/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8930394/2e67ff0f6f1d/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8930394/52a7b30e409a/figs1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8930394/fbf0e4e6da65/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8930394/7d9adba156d1/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8930394/9fad7a9944fb/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20ba/8930394/758c9ab78bdd/gr4_lrg.jpg

相似文献

1
Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.疫苗突破感染中来自 SARS-CoV-2 奥密克戎和德尔塔变异株的中和抗体免疫。
Cell. 2022 Apr 28;185(9):1539-1548.e5. doi: 10.1016/j.cell.2022.03.019. Epub 2022 Mar 18.
2
Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.COVID-19 患者在突破感染 SARS-CoV-2 变异株 Delta、Omicron-BA.1 和 Omicron-BA.5 期间的免疫反应。
Front Immunol. 2023 Jul 13;14:1150667. doi: 10.3389/fimmu.2023.1150667. eCollection 2023.
3
Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.野生型 SARS-CoV-2 中和抗体的免疫活性会随着时间推移和变异株的不同而降低,但与诊断检测有很好的相关性。
Front Immunol. 2023 Feb 8;14:1055429. doi: 10.3389/fimmu.2023.1055429. eCollection 2023.
4
Neutralizing Immunity Induced Against the Omicron BA.1 and BA.2 Variants in Vaccine Breakthrough Infections.疫苗突破性感染中针对奥密克戎 BA.1 和 BA.2 变异株诱导的中和免疫。
J Infect Dis. 2022 Nov 11;226(10):1688-1698. doi: 10.1093/infdis/jiac384.
5
Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.接种疫苗和奥密克戎 BA.1/BA.2 感染恢复期增强了针对 BA.4/5 的系统性但非黏膜免疫。
Microbiol Spectr. 2023 Jun 15;11(3):e0516322. doi: 10.1128/spectrum.05163-22. Epub 2023 Apr 26.
6
Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.奥密克戎亚变体的中和敏感性、融合性和感染性。
Genome Med. 2022 Dec 29;14(1):146. doi: 10.1186/s13073-022-01151-6.
7
Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals.突破性感染德尔塔变异株后 COVID-19 疫苗接种者对 SARS-CoV-2 变异株(包括奥密克戎)的广泛中和作用。
mBio. 2022 Apr 26;13(2):e0379821. doi: 10.1128/mbio.03798-21. Epub 2022 Mar 17.
8
Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.奥密克戎突破性感染中针对 SARS-CoV-2 体液免疫的独特特征。
Vaccine. 2023 Nov 13;41(47):7019-7025. doi: 10.1016/j.vaccine.2023.10.035. Epub 2023 Oct 17.
9
Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.中国天津地区针对 SARS-CoV-2 奥密克戎 BA.1 变异株疫苗突破性感染后五种 SARS-CoV-2 变异株的中和抗体反应和 T 淋巴细胞变化的前瞻性研究。
Biomed Environ Sci. 2023 Jul 20;36(7):614-624. doi: 10.3967/bes2023.047.
10
Age-Related Differences in Neutralizing Antibody Responses against SARS-CoV-2 Delta and Omicron Variants in 151 SARS-CoV-2-Naïve Metropolitan Residents Boosted with BNT162b2.151名未感染过SARS-CoV-2的大城市居民接种BNT162b2疫苗后,针对SARS-CoV-2 Delta和Omicron变体的中和抗体反应的年龄相关差异
J Appl Lab Med. 2024 Jul 1;9(4):741-751. doi: 10.1093/jalm/jfae014.

引用本文的文献

1
Leaky or polarised immunity: Non-Markovian modelling highlights the impact of immune memory assumptions.渗漏或极化免疫:非马尔可夫模型突出了免疫记忆假设的影响。
PLoS Comput Biol. 2025 Aug 19;21(8):e1013399. doi: 10.1371/journal.pcbi.1013399. eCollection 2025 Aug.
2
Epidemiological features and risk factors of SARS-CoV-2 reinfection: a retrospective cohort analysis in Xiamen, China.新型冠状病毒2型再次感染的流行病学特征及危险因素:中国厦门的一项回顾性队列分析
J Thorac Dis. 2025 Jul 31;17(7):4732-4745. doi: 10.21037/jtd-24-1703. Epub 2025 Jul 28.
3
Differential immunity induced by Omicron sublineages in naïve and vaccine breakthrough infections.

本文引用的文献

1
Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.奥密克戎突变增强了 SARS-CoV-2 病毒样颗粒的感染力,并降低了抗体的中和作用。
Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2200592119. doi: 10.1073/pnas.2200592119. Epub 2022 Jul 19.
2
Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa.在南非西开普省,与之前的几波疫情相比,奥密克戎驱动的第四波疫情中实验室确诊的 SARS-CoV-2 感染的结果。
Trop Med Int Health. 2022 Jun;27(6):564-573. doi: 10.1111/tmi.13752. Epub 2022 May 10.
3
奥密克戎亚谱系在初次感染和疫苗突破性感染中诱导的差异性免疫。
Sci Rep. 2025 Jul 3;15(1):23718. doi: 10.1038/s41598-025-07702-2.
4
Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection.抗体水平及预防奥密克戎BQ.1/XBB突破性感染的决定因素
Commun Med (Lond). 2025 Jun 20;5(1):243. doi: 10.1038/s43856-025-00943-2.
5
Which test results to believe? Comparison of different ELISA kits for detection of SARS-CoV-2-neutralizing antibody among COVID-vaccinated individuals.该相信哪些检测结果?新冠疫苗接种者中不同ELISA试剂盒检测新型冠状病毒中和抗体的比较。
Med J Armed Forces India. 2025 May-Jun;81(3):320-327. doi: 10.1016/j.mjafi.2024.05.014. Epub 2024 Jul 4.
6
Use of a Multiplex Immunoassay Platform to Investigate Multifaceted Antibody Responses in SARS-CoV-2 Vaccinees with and Without Prior Infection.使用多重免疫分析平台研究有或无既往感染的新冠病毒疫苗接种者的多方面抗体反应。
COVID. 2025 Apr;5(4). doi: 10.3390/covid5040044. Epub 2025 Mar 22.
7
Immunological analysis of LC16m8 vaccine: preclinical and early clinical insights into mpox.LC16m8疫苗的免疫学分析:猴痘的临床前和早期临床见解
EBioMedicine. 2025 May;115:105703. doi: 10.1016/j.ebiom.2025.105703. Epub 2025 Apr 15.
8
Effectiveness of inactivated COVID-19 vaccine against symptom severity in hospitalized COVID-19 patients infected with the Omicron variant.新冠病毒灭活疫苗对感染奥密克戎变异株的住院新冠肺炎患者症状严重程度的有效性
Arch Virol. 2025 Mar 24;170(5):88. doi: 10.1007/s00705-025-06275-9.
9
SARS-CoV-2 serotyping based on spike antigenicity and its implications for host immune evasion.基于刺突抗原性的严重急性呼吸综合征冠状病毒2血清分型及其对宿主免疫逃逸的影响
EBioMedicine. 2025 Apr;114:105634. doi: 10.1016/j.ebiom.2025.105634. Epub 2025 Mar 12.
10
Covalent inhibition of the SARS-CoV-2 NiRAN domain via an active-site cysteine.通过活性位点半胱氨酸对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)核苷酸转移酶/RNA帽甲基转移酶(NiRAN)结构域进行共价抑制。
J Biol Chem. 2025 Apr;301(4):108378. doi: 10.1016/j.jbc.2025.108378. Epub 2025 Mar 4.
SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)突破性感染引发强效、广泛且持久的中和抗体反应。
Cell. 2022 Mar 3;185(5):872-880.e3. doi: 10.1016/j.cell.2022.01.011. Epub 2022 Jan 20.
4
SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo.严重急性呼吸综合征冠状病毒2型奥密克戎变异株在人支气管和肺组织外植体中的复制
Nature. 2022 Mar;603(7902):715-720. doi: 10.1038/s41586-022-04479-6. Epub 2022 Feb 1.
5
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.通过感染或接种疫苗,三次接触 SARS-CoV-2 的刺突蛋白会引发对所有令人关注的变异体更好的中和免疫。
Nat Med. 2022 Mar;28(3):496-503. doi: 10.1038/s41591-022-01715-4. Epub 2022 Jan 28.
6
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study.南非对 SARS-CoV-2 奥密克戎变异株临床严重程度的早期评估:一项数据关联研究。
Lancet. 2022 Jan 29;399(10323):437-446. doi: 10.1016/S0140-6736(22)00017-4. Epub 2022 Jan 19.
7
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters.新冠病毒奥密克戎变异株在小鼠和仓鼠中引起轻症疾病。
Nature. 2022 Mar;603(7902):687-692. doi: 10.1038/s41586-022-04441-6. Epub 2022 Jan 21.
8
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.一种传染性 SARS-CoV-2 B.1.1.529 奥密克戎病毒能够逃避治疗性单克隆抗体的中和作用。
Nat Med. 2022 Mar;28(3):490-495. doi: 10.1038/s41591-021-01678-y. Epub 2022 Jan 19.
9
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.mRNA 加强免疫可引发针对 SARS-CoV-2 奥密克戎变异株的强效中和血清活性。
Nat Med. 2022 Mar;28(3):477-480. doi: 10.1038/s41591-021-01676-0. Epub 2022 Jan 19.
10
Omicron, the great escape artist.奥密克戎,杰出的逃脱大师。
Nat Rev Immunol. 2022 Feb;22(2):75. doi: 10.1038/s41577-022-00676-6.